Syncona leads £88.4m series-B for Freeline

Syncona contributed £85m to the financing round, while University College London's UCL Technology Fund contributed £3.4m. The investment will comprise a number of different tranches, with the first tranche consisting of £30m.

The fresh capital will enable the company to undertake clinical trials for its haemophilia B programme; expand its range of products; invest in manufacturing equipment and facilities; and move towards commercialisation.

Syncona will have an 80% stake in the company following the latest round.

Previous funding
Syncona was a founding investor in Freeline alongside UCL, and has provided £33.5m in series-A funding for the company since 2015.

Company
Founded in 2015, Freeline is a clinical stage company specialising in adeno-associated virus gene therapy and focused on liver expression for chronic systemic diseases.

People
Syncona – Chris Hollowood (chief investment officer).
Freeline – Anne Prener (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland
• Healthcare
• United Kingdom
• Venture